SND002 / Jiangsu Sinorda Biomedicine - LARVOL DELTA

Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors (Businesswire) - "Suzhou Porton Advanced Solutions Ltd...announced a long-term strategic partnership in cell and gene therapy R&D and platform development....Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine, including its T-cell immunotherapy product for colorectal cancer, SND002 (Sentinel lymph node T cell) and other pipelines....SND002 (SLN-T), the first collaborated project, has received approval for the initiation of Phase II clinical trials in Europe."

Licensing / partnership • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor